Chronic idiopathic myelofibrosis: Clinicopathologic features, pathogenesis, and prognosis

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 8, 2006, Pages 1133-1143

  Ahmed, Arsalan ^a   Chang, Chung Che ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BCR ABL PROTEIN; CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR; JANUS KINASE 2; PLATELET DERIVED GROWTH FACTOR; STAT PROTEIN; TRANSCRIPTION FACTOR GATA 1; TRANSFORMING GROWTH FACTOR BETA;

AGE; ANEMIA; ANGIOGENESIS; BLAST CELL; BONE MARROW BIOPSY; CHRONIC IDIOPATHIC MYELOFIBROSIS; CLINICAL FEATURE; CYTOGENETICS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; ENDOTHELIUM CELL; EXTRAMEDULLARY HEMATOPOIESIS; GENE MUTATION; HEMATOPOIETIC STEM CELL; HEPATOMEGALY; HUMAN; LEUKEMIA; LEUKOCYTE COUNT; MEDLINE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPHTHISIC ANEMIA; MYELOPROLIFERATIVE DISORDER; OSTEOSCLEROSIS; PATHOGENESIS; POLYCYTHEMIA VERA; PROGNOSIS; REVIEW; SPLENOMEGALY;

BIOLOGICAL MARKERS; BONE MARROW; HEMATOPOIESIS, EXTRAMEDULLARY; HUMANS; JANUS KINASE 2; MYELOFIBROSIS; POINT MUTATION; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 33746740093     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours; vol 3.
2. Ridell B, Carneskog J, Wedel H, et al. Incidence of chronic myeloproliferative disorders in the city of Goteborg, Sweden 1983-1992. Eur J Haematol. 2000;65: 267-271.
3. Mesa RA, Tefferi A. Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Semin Oncol. 2005;32:403-413.
4. Sekhar M, Prentice HG, Popat U, et al. Idiopathic myelofibrosis in children. Br J Haematol. 1996;93:394-397.
5. Bonduel M, Sciuccati G, Torres AF, Pierini A, Gallo G. Familial idiopathic myelofibrosis and multiple hemangiomas. Am J Hematol. 1998;59:175-177.
6. Altura RA, Head DR, Wang WC. Long-term survival of infants with idiopathic myelofibrosis. Br J Haematol. 2000;109:459-462.
7. Tefferi A, Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342: 1255-1265.
8. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis; a study of 106 cases. Br J Haematol. 1997;98:96-102.
9. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96:3374-3380.
10. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003; 101:1981-1983.
11. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol. 1994;86:233-235.
12. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol. 1985;61:657-666.
13. Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemias: clinical evolutionary and biological data. Cancer. 1986;58:2440-2447.
14. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol. 1997;97:441-448.
15. Schmitt A, Drouin A, Masse JM, Guichard J, Shagraoui H, Cramer EM. Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis. Leuk Lymphoma. 2002;43:719-724.
16. Klagsbrun M. The fibroblast growth factor family: structural and biological properties. Prog Growth Factor Res. 1989;1:207-235.
17. Charbord P. Increased vascularity of bone marrow in myelofibrosis. Br J Haematol. 1986;62:595-596.
18. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol. 2000;157:15-19.
19. Vannucchi AM, Bianchi L, Paoletti F, et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TCF-beta1 in the development of myelofibrosis. Blood. 2005;105:3493-3501.
20. Di Raimondo F, Azzaro MP, Palumbo GA, et al. Elevated vascular endothelial growth factor (VECF) serum levels in idiopathic myelofibrosis. Leukemia. 2001; 15:976-980.
21. Chou JM, Li CY, Tefferi A. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. Leuk Res. 2003;27:499-504.
22. Xu M, Bruno E, Chao J, et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood. 2005;105:4508-4515.
23. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood. 1999; 93:3379-3390.
24. Wilkins BS, Green A, Wild AE, Jones DB. Extramedullary haemopoiesis in fetal and adult human spleen: a quantitative immunohistological study. Histopathology. 1994;24:241-247.
25. Wolf BC, Neiman RS. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood. 1985;65:803-809.
26. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997;80:708-719.
27. Porcu P, Neiman RS, Orazi A. Splenectomy in agnogenic myeloid metaplasia. Blood. 1999;93:2132-2134.
28. O'Malley DP, Orazi A, Wang M, Cheng L. Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia. Mod Pathol. 2005;18:1562-1568.
29. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103:399-406.
30. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93:2867-2875.
31. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood. 2002;100:1123-1132.
32. Vannucchi AM, Pancrazzi A, Guglielmelli P, et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol. 2005;167:849-858.
33. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood. 1997;90:4031-4038.
34. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med. 1998;338:572-580.
35. Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 2003;102; 1869-1871.
36. Harrison CN, Gale RE, Pezella F, Mire-Sluis A, MacHin SJ, Linch DC. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. Br J Haematol. 1999;107:139-147.
37. Le Blanc K, Andersson P, Samuelsson J. Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera. Br J Haematol. 2000;108:80-85.
38. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998;18:49-52.
39. Jones LC, Tefferi A, Idos GE, Kumagai T, Hofmann WK, Koeffler HP. RAR-beta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene. 2004;23:7846-7853.
40. Cervantes F, Barosi G. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging. Semin Oncol. 2005;32:395-402.
41. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders: incidence among subtypes according to the Hannover Classification. Pathol Res Pract. 1993;189:121-132.
42. Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF): a clinicopathological study. Leukemia. 1999;13:1741-1748.
43. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels J. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma. 1999;33:207-218.
44. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol. 1998;11:721-749.
45. Thiele J, Zirbes TK, Kvasnicka HM, Fischer R. Focal lymphoid aggregates (nodules) in bone marrow biopsies: differentiation between benign hyperplasia and malignant lymphoma: a practical guideline. J Clin Pathol. 1999;52:294-300.
46. Dickstein JI, Vardiman JW. Hematopathologic findings in the myeloproliferative disorders. Semin Oncol. 1995;22:355-373.
47. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4-9.
48. Eaton P, Byers HL, Leeds N, Ward MA, Shattock MJ. Detection, quantitation, purification, and identification of cardiac proteins S-thiolated during ischemia and reperfusion. J Biol Chem. 2002;277:9806-9811.
49. Thiele J, Zankovich R, Steinberg T, Fischer R, Diehl V. Agnogenic myeloid metaplasia (AMM): correlation of bone marrow lesions with laboratory data: a longitudinal clinicopathological study on 114 patients. Hematol Oncol. 1989;7: 327-343.
50. Thiele J, Bennewitz FG, Bertsch HP, Falk S, Fischer R, Stutte HJ. Splenic haematopoiesis in primary (idiopathic) osteomyelofibrosis: immunohistochemical and morphometric evaluation of proliferative activity of erytro- and endoreduplicative capacity of megakaryopoiesis (PCNA- and Ki-67 staining). Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64:281-286.
51. Falk S, Mix D, Stutte HJ. The spleen in osteomyelofibrosis: a morphological and immunohistochemical study of 30 cases. Virchows Arch A Pathol Anat Histopathol. 1990;416:437-442.
52. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol. 2002;76:133-145.
53. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol. 2003;82:148-152.
54. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104:730-737.
55. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128-1132.
56. Passamonti F, Vanelli L, Malabarba L, et al. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica. 2003;88:1123-1129.
57. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249-3255.
58. Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol. 2005;128:42-48.
59. Andreasson B, Swolin B, Kutti J. Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol. 2002; 68:189-193.
60. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularizatioh and regeneration. Nat Med. 2003;9:702-712.
61. Massa M, Rosti V, Ferrario M, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005;105:199-206.
62. Massa M, Rosti V, Ramajoli I, et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23:5688-5695.
63. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996; 88:1013-1018.
64. Dingli D, Grand FH, Mahaffey V, et al. Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. Br J Haematol. 2005;130:229-232.
65. Reilly JT. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia. Semin Oncol. 2005;32:359-364.
66. Al-Assar O, Ul-Hassan A, Brown R, Wilson GA, Hammond DW, Reilly JT. Gains on 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study. Br J Haematol. 2005;129:66-71.
67. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209.
68. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109(suppl):121-131.
69. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385-395.
70. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
71. James C, Ugo V, LeCouedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
72. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
73. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
74. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
75. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788-22792.
76. Georgii A, Vykoupil KF, Buhr T, et al. Chronic myeloproliferative disorders in bone marrow biopsies. Pathol Res Pract. 1990;186:3-27.
77. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987;59:1739-1743.
78. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277-280.
79. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature. 1973;243:290-293.
80. Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis: a clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore). 1983;62:353-371.
81. Annaloro C, Lambertenghi Deliliers G, Oriani A, et al. Prognostic significance of bone marrow biopsy in essential thrombocythemia. Haematologica. 1999;84:17-21.
82. Ellis JT, Peterson P, Geller SA, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol. 1986;23:144-155.
83. Maschek H, Georgii A, Kaloutsi V, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol. 1992; 48:208-214.
84. Pagliuca A, Layton DM, Manoharan A, Gordon S, Green PJ, Mufti GJ. Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. Br J Haematol. 1989;71:499-504.
85. Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol. 1991;78:161-166.
86. Sultan C, Sigaux F, Imbert M, Reyes F. Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol. 1981;49:11-16.
87. Ozen S, Ferhanoglu B, Senocak M, Tuzuner N. Idiopathic myelofibrosis (agnogenic myeloid metaplasia): clinicopathological analysis of 32 patients. Leuk Res. 1997;21:125-131.
88. Verhoef GE, De Wolf-Peeters C, Ferrant A, et al. Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol. 1991;63:235-241.
89. Reilly JT, Dolan G. Proposed classification for the myelodysplasia/ myelofibrosis syndromes. Br J Haematol. 1991;79:653.
90. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
91. Lewis SM, Szur L. Malignant myelosclerosis. Br Med J. 1963;5355:472-477.
92. Bearman RM, Pangalis GA, Rappaport H. Acute ("malignant") myelosclerosis. Cancer 1979;43:279-293.
93. Bird T, Proctor SJ. Malignant myelosclerosis: myeloproliferative disorder or leukemia? Am J Clin Pathol. 1977;67:512-520.
94. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97: 635-640.
95. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia: Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood. 1998;91:3630-3636.
96. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105:973-977.
97. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70: 397-401.
98. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763-771.
99. Sagaster V, Jager E, Weltermann A, et al. Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia. Haematologica. 2003;88:1204-1212.
100. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol. 2001;73:194-198.
101. Kreft A, Weiss M, Wiese B, et al. Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages: a retrospective study identifying subgroups of different prognoses by using the RECPAM method. Ann Hematol. 2003;82:605-611.